<DOC>
	<DOCNO>NCT02559960</DOCNO>
	<brief_summary>This registry aim monitor safety Breviscapine Powder-Injection identify potential risk factor adverse drug reaction .</brief_summary>
	<brief_title>Post-marketing Safety Surveillance Breviscapine Powder-Injection : Registry Study</brief_title>
	<detailed_description>Breviscapine Powder-Injection kind natural compound injection high purity Scutellarin-Na ( 98 % ) . It 's popular drug ischemic disease , cerebral ischemic stroke , coronary heart disease angor pectoris . However , case report adverse drug event Chinese medicine injection extract Dengzhanhua ( herba erigernotis ) ( Breviscapine one common compound ) report recent 10 year . Therefore , registry Breviscapine Powder-Injection aim monitor safety Breviscapine Powder-Injection identify potential risk factor adverse drug reaction .</detailed_description>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Anaphylaxis</mesh_term>
	<criteria>Patients use Breviscapine PowderInjection monitoring department centain hospital</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>